IBRX261106C00009500
IBRX Nov 6 2026 9.50 Call
optionOPRA
EODOct 16, 2026
0.70USD-48.905%(-0.67)22Vol35OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
9.5
Expiration
Nov 6, 2026
DTE
17d
Moneyness
OTM
Intrinsic
$0.00
IBRX 9.5 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.28 | -65.00% | 263 | 438 |
| Oct 30, 2026 | 10d | $1.24 | +1.64% | 8 | 114 |
| Nov 6, 2026 | 17d | $0.70 | -48.91% | 22 | 35 |
| Nov 13, 2026 | 24d | $0.88 | -39.73% | 214 | 221 |
| Nov 27, 2026 | 38d | $1.20 | -41.46% | 12 | 20 |
IBRX Nearby Strikes · Nov 6, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 6.5 C | $4.13 | +67.21% | 1 | 1 | ITM |
| 7 C | $3.28 | -9.64% | 1 | 4 | ITM |
| 7.5 C | — | — | 0 | 0 | ITM |
| 8 C | $1.85 | -31.23% | 10 | 507 | ITM |
| 8.5 C | $2.20 | +37.50% | 4 | 4 | OTM |
| 9 C | $1.10 | -26.17% | 18 | 64 | OTM |
| 9.5 C | $0.70 | -48.91% | 22 | 35 | OTM |
| 10 C | $0.70 | -30.00% | 65 | 125 | OTM |
| 10.5 C | $0.65 | -14.47% | 4 | 44 | OTM |
| 11 C | $0.45 | -18.18% | 34 | 379 | OTM |
| 11.5 C | $0.35 | -38.60% | 2 | 39 | OTM |
| 12 C | $0.40 | -18.37% | 17 | 307 | OTM |
| 12.5 C | $0.10 | -74.36% | 1 | 22 | OTM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.